JYSK and Lars Larsen Group donate DKK 1 million to Knæk Cancer

Again this year, JYSK and Lars Larsen Group are donating DKK 1 million to Kræftens Bekæmpelse (Danish Cancer Society) in connection with TV 2’s fundraising show ‘Knæk Cancer’ to support research projects, prevention, and patients living with cancer.

According to Kræftens Bekæmpelse, four in ten people in Denmark will develop cancer before the age of 80. Approximately 420,000 people in Denmark are living with or have had cancer, and even more are close to someone affected by the disease.

Cancer research ensures advances and the development of new treatment options, which means that more people survive cancer. Although research continues to achieve new results, there is still a considerable need for support for further research projects in the fight against cancer.

“Cancer affects many people, both those living with the disease and those close to them. By supporting Knæk Cancer, we want to contribute to research, prevention, and better support for patients and their families,” says Jesper Lund, President & CEO of Lars Larsen Group.

“Through our support for Knæk Cancer, we want to make a real difference for people affected by cancer and contribute to the research and initiatives that drive progress, bring hope, and create better opportunities for both patients and those close to them,” he concludes.

How the Knæk Cancer funds will be used in 2026

This year marks the 15th consecutive year of fundraising for Knæk Cancer. According to the Knæk Cancer website, 594 projects have been launched over the years, made possible by the support of the Danish public and the funds raised.

Again this year, Kræftens Bekæmpelse has highlighted a number of relevant focus areas within prevention, research, and patient support that could potentially receive funding from this year’s Knæk Cancer fundraising campaign:

• Børnecancerfonden
• Improved understanding of long-term effects
• Cancer from a population and societal perspective
• Unge talentfulde kræftforskere
• Professorship in the long-term effects of cancer and cancer treatment
• Multimorbidity, ageing, and cancer
• From promising findings to new cancer treatments
• Better use of data for better treatment
• Coordinated cancer care pathways
• Den danske kræftkohorte

Source: Support Knæk Cancer and create hope | Knæk Cancer 2026